Dudediligence.

BridgeBio Pharma, Inc

BBIONASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

195.3M

on 2026-06-30, from 187.1M on 2024-03-31 10-Q ↗

50M100M150M200MMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

No limit

S-3ASR of 2026-05-08. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$500.0M

Goldman Sachs, agreement of 2026-05-08. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

The 10-Q filed 2026-08-10 is not read yet.

Cash

6.6 quarters

$720.2M on 2026-06-30 ÷ $108.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 3 of its filings are not read yet.

Also on file: $82.5M convertible notes, 2026-01-21 8-K ↗